Technical Ventures RX Corp.

November 07, 2014 14:35 ET

Technical Ventures RX Corp. and TheraVitae Inc. Announce Shareholder Approval of Plan of Arrangement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 7, 2014) - Technical Ventures RX Corp. ("Technical") (TSX VENTURE:TIK.P) and TheraVitae Inc. ("TheraVitae") are pleased to announce that our respective shareholders have approved all matters related to the proposed combination of Technical and TheraVitae originally announced on July 25, 2013 and detailed in the Amended and Restated Joint Management Information Circular and Proxy Statement ("Joint Circular") dated September 30, 2014. There were no dissenting shareholders.

The Arrangement is expected to be completed on November 10, 2014 upon satisfaction or waiver of all of the conditions to the Arrangement set out in the Arrangement Agreement entered into by Technical and TheraVitae on July 19, 2013, as amended, including approval by the Court of Queen's Bench of Alberta at a hearing scheduled for November 7, 2014 and TSXV approvals. Upon completion of the Arrangement, Technical will acquire all the outstanding securities of TheraVitae through the issuance of Technical securities and Technical will change its name to Hemostemix Inc. A further news release regarding the closing of the Arrangement, concurrent financings, and resumption of trading on the TSXV will be issued after the Arrangement has closed.

Full details regarding the terms of the Arrangement are set out in the Joint Circular which is available on SEDAR at

Description of Significant Conditions to Closing

Completion of the Arrangement is subject to a number of conditions, as noted in prior news releases. There can be no assurance that the Arrangement will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the information circular, any information released or received with respect to the Arrangement may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Qualifying Transaction and associated transactions and has neither approved nor disapproved of the contents of this press release.

Contact Information

  • Technical Ventures RX Corp.
    David L. Wood
    President and Chief Executive Officer
    (604) 720-7307

    TheraVitae Inc.
    Charles W. Baker
    chairman and Director
    (403) 818-7672